NCT06770894View on ClinicalTrials.gov

DPP4-Inhibitors and Bone Metabolism in Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

September 24, 2019

Primary Completion Date

October 10, 2023

Study Completion Date

January 24, 2024

Conditions
OsteoporosisBone Loss, PostmenopausalDiabetes Mellitus Type 2
Interventions
DRUG

Sitagliptin 100 mg

The study population will be randomly allocated in either intervention or placebo arm (1:1). Treatment (sitagliptin 100 mg) and placebo will be provide in identical packages by an experienced independent pharmacist. The recommended intake is one tablet a day, equivalent to sitagliptin 100 mg in the active-treated group, for the duration of the study (52 weeks)

DRUG

Placebo Tablets

Placebo tablets 1 a day, provided in identical blisters.

Trial Locations (1)

00161

AOU Policlinico Umberto I, University La Sapienza, Rome

All Listed Sponsors
collaborator

Agenzia Italiana del Farmaco

OTHER_GOV

lead

Azienda Policlinico Umberto I

OTHER

NCT06770894 - DPP4-Inhibitors and Bone Metabolism in Diabetes | Biotech Hunter | Biotech Hunter